- Home
- ANVS vs IMAB Comparison
ANVS vs IMAB Comparison
Compare ANVS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- IMAB
- Stock Information
- Founded
- ANVS 2008
- IMAB 2014
- Country
- ANVS United States
- IMAB United States
- Employees
- ANVS 6
- IMAB N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- IMAB Health Care
- Exchange
- ANVS Nasdaq
- IMAB Nasdaq
- Market Cap
- ANVS 44.6M
- IMAB 200.9M
- IPO Year
- ANVS 2020
- IMAB 2020
- Fundamental
- Price
- ANVS $2.38
- IMAB $2.29
- Analyst Decision
- ANVS Strong Buy
- IMAB Strong Buy
- Analyst Count
- ANVS 5
- IMAB 2
- Target Price
- ANVS $30.25
- IMAB $6.00
- AVG Volume (30 Days)
- ANVS 607.7K
- IMAB 1.0M
- Earning Date
- ANVS 08-14-2025
- IMAB 05-15-2025
- Dividend Yield
- ANVS N/A
- IMAB N/A
- EPS Growth
- ANVS N/A
- IMAB N/A
- EPS
- ANVS N/A
- IMAB N/A
- Revenue
- ANVS N/A
- IMAB N/A
- Revenue This Year
- ANVS N/A
- IMAB N/A
- Revenue Next Year
- ANVS N/A
- IMAB N/A
- P/E Ratio
- ANVS N/A
- IMAB N/A
- Revenue Growth
- ANVS N/A
- IMAB N/A
- 52 Week Low
- ANVS $1.11
- IMAB $0.60
- 52 Week High
- ANVS $17.88
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- ANVS 48.74
- IMAB 53.66
- Support Level
- ANVS $2.05
- IMAB $2.00
- Resistance Level
- ANVS $3.18
- IMAB $2.95
- Average True Range (ATR)
- ANVS 0.27
- IMAB 0.35
- MACD
- ANVS -0.09
- IMAB -0.07
- Stochastic Oscillator
- ANVS 29.20
- IMAB 30.53
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).